Dyne Therapeutics, Inc. · BX:DYN

Dyne Therapeutics, Inc. financial statements

Dyne Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000000506.0M1.37B
Cost of revenue2.05M2.24M2.46M3.35M1.09M700.0K271.0K24.0K2.93B2.28B
Gross profit-2.05M-2.24M-2.46M-3.35M-1.09M-700.0K-271.0K-24.0K-2.43B-915.0M
Research and development398.3M281.4M210.8M142.8M121.3M45.2M11.0M4.28M
Selling, general and administrative69.9M62.5M31.4M28.2M28.7M13.4M2.79M517.0K189.0M161.0M
Operating income-468.2M-343.9M-242.2M-171.0M-150.0M-58.6M-13.8M-4.79M-412.0M-640.0M
Depreciation and amortization2.05M1.67M1.67M1.68M1.09M700.0K271.0K24.0K867.0M766.0M
EBITDA-466.1M-342.2M-240.5M-169.3M-148.9M-57.9M-13.6M-4.77M455.0M126.0M
Interest expense6.19M002.92M742.0K396.0K290.0K5.00K616.0M625.0M
Income before tax-446.2M-317.4M-235.9M-168.1M-149.3M-59.4M-14.9M-4.81M-538.0M-1.29B
Income tax000-2.86M-8.00K-700.0K-1.32M-11.0K-610.0M-45.0M
Net income-446.2M-317.4M-235.9M-168.1M-149.3M-59.4M-14.9M-4.81M76.0M-1.24B
Earnings per share, basic-3.47-3.37-3.95-3.23-2.93-4.13-6.08-0.470.47-9.61
Earnings per share, diluted-3.47-3.37-3.95-3.23-2.93-4.13-6.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents893.4M435.4M121.6M172.1M200.8M300.9M14.6M8.12M365.0M1.78B
Short-term investments217.2M206.8M1.47M83.9M175.7M44.5M032.0M130.0M
Receivables513.0M386.0M
Inventory445.0M445.0M
Current assets1.13B659.3M129.4M265.6M382.4M349.1M14.8M8.16M1.52B2.99B
Property, plant and equipment24.0M5.40M4.78M5.95M4.68M1.95M1.49M110.0K
Goodwill772.0M799.0M
Total assets1.19B691.2M165.1M306.3M425.7M353.3M16.4M8.27M11.8B13.1B
Accounts payable8.08M6.56M22.9M5.26M4.03M3.44M1.26M518.0K367.0M332.0M
Current liabilities50.6M42.3M51.1M28.1M28.7M11.0M2.36M711.0K1.05B916.0M
Long-term debt148.9M
Total debt148.9M027.4M30.5M32.6M3.38M8.43B8.98B
Total liabilities214.8M61.4M73.8M54.0M57.5M11.0M2.40M13.1M9.87B11.0B
Shareholders' equity972.1M629.8M91.3M252.4M368.2M342.4M14.0M-4.88M1.90B2.04B
Shares outstanding165.0M102.3M61.5M55.6M51.6M45.1M2.59M10.3M162.0M129.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-403.2M-292.4M-188.2M-153.6M-119.6M-46.5M-11.8M-4.16M585.0M676.0M
Capital spending-1.92M-2.38M-729.0K-3.07M-3.62M-1.16M-1.65M-134.0K-224.0M-326.0M
Free cash flow-405.1M-294.7M-188.9M-156.7M-123.2M-47.7M-13.5M-4.30M361.0M350.0M
Cash from investing-28.8M-204.1M83.3M87.2M-137.9M-45.7M-1.65M-134.0K-2.76B-2.15B
Cash from financing890.3M809.9M54.3M37.4M157.8M380.7M20.0M12.4M-1.30B2.74B
Dividends paid-22.0M-22.0M
Share buybacks20.0M7.42M
Change in cash458.3M313.4M-50.5M-29.1M-99.6M288.5M6.51M12.4M-3.47B1.27B